May 13, 2020 / 9:18 PM / 21 days ago

BRIEF-BridgeBio's Phoenix Tissue Repair Provides Updates To Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program

May 13 (Reuters) - BridgeBio Pharma Inc:

* BRIDGEBIO PHARMA’S PHOENIX TISSUE REPAIR PROVIDES UPDATES TO ITS RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA (RDEB) PROGRAM AND ANNOUNCES NEW LEADERSHIP APPOINTMENTS

* BRIDGEBIO PHARMA - BASED ON INTERIM REVIEW OF DATA PTR-01 WAS WELL TOLERATED & THERE HAVE BEEN NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS AT ANY DOSE Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below